logo
  • About
    • The Idea
    • The Concept
    • Strategy
  • Opportunity
    • The Need
    • The Market
    • The Unique Concept
    • The Competition
  • Scientific Foundation
    • Knowledge Platform
    • Modes of Action
    • Results
    • IPR
  • Publications
  • Team
  • News
  • Contact
papp scen
  1. Home
  2. News
  3. Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa
  4. papp scen

© 2025 Xinnate. All rights reserved